Aspects of post-COVID asthenia symptoms correction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Taking into account the high incidence and duration of asthenic syndrome (AS), one can say that therapy of it is an urgent clinical problem in the practice of primary care physicians. Current article provides actual data on the prevalence of its main symptoms among patients with chronic noncontagious diseases and after surviving a novel coronavirus infection. Clinical manifestations and principles of AS diagnosing, including those in the post-COVID period, are discussed, perspectives for the management and treatment of patients with this condition are considered, and the mechanism of action of Stimol medicine in relation to that category of patients is analyzed in details.

Full Text

Restricted Access

About the authors

V. N Shishkova

National Medical Research Center of Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Email: veronika-13060mail.ru
101990, Moscow, 10 Petroverigsky Lane

References

  1. Порошина Е.Г., Немировский В.С. Астения, неврастения, синдром хронической усталости: сходство и различия. Учебнометодическое пособие. Под ред. проф. В.И. Симаненкова. СПб. 2012; 42 с. @@Poroshina E.G., Nemirovsky V.S. Asthenia, neurasthenia, chronic fatigue syndrome: similarities and differences. Educational toolkit. Ed. by Simanenkov V.I. Saint Petersburg. 2012; 42 pp. (In Russ.)
  2. Шишкова В.Н. Весенний сезон острых респираторных инфекций: что это означает для коморбидного пациента и как к нему подготовиться. Лечебное дело. 2019; 4: 122-128. @@Shishkova V.N. Spring season of acute respiratory infections: what does it mean for comorbid patient and how to prepare for it. Lechebnoe delo = General Medicine. 2019; 4: 122-128 (In Russ.)]. doi: 10.24411/2071-5315-2019-12166.
  3. Stormorken E., Jason L.A., Kirkevold M. From good health to illness with post-infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. BMC Fam Pract. 2017; 18(1): 49-52. doi: 10.1186/s12875-017-0614-4.
  4. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585
  5. Stavem K., Ghanima W., Olsen M.K. et al. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study.Int J Environ Res Public Health. 2021; 18(4): 2030. doi: 10.3390/ijerph18042030
  6. Callis A., Magnan de Bornier B., Serrano J.J. et al. Activity of citrulline malate on acid-base balance and blood ammonia and amino acid levels. Study in the animal and in man. Arzneimittelforschung 1991; 41(6): 660-63.
  7. Емельянов В.В., Максимова Н.Е., Мочульская Н.Н. Биохимия: учебное пособие. Екатеринбург: Издательство Уральского университета. 2016; 132 с. @@Emelyanov V.V., Maksimova N.E., Mochulskaya N.N. Biochemistry: textbook. Yekaterinburg: Ural University Press. 2016; 132 pp. (In Russ.)
  8. Bendahan D., Mattei J.P., Ghattas B. et al. Citrulline/malate promotes aerobic energy production in human exercising muscle. Br J Sports Med. 2002; 36(4): 282-9. doi: 10.1136/bjsm.36.4.282
  9. Orea-Tejeda A., Orozco-Gutierrez J.J., Castillo Martinez L. et al. The effect of L-arginine and citrulline on endothelial function in patients in heart failure with preserved ejection fraction. Cardiol J. 2010; 17(5): 464-70.
  10. Торшин И.Ю., Громова О.А., Федотова Л.Э. с соавт. Хемореактомный анализ молекул цитруллина и малата. Неврология, нейропсихиатрия, психосоматика. 2017; 2: 30-35. @@Torshin I.Yu., Gromova O.A., Fedotova L.E. et al. CHEMOREACTOMIC Analysis of citrulline malate molecules. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017; 2: 30-35 (In Russ.)]. doi: 10.14412/2074-2711-2017-2-30-35
  11. Yabuki Y., Shioda N., Yamamoto Y. et al. Oral L-citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection. Brain Res. 2013; 1520: 157-67. doi: 10.1016/j.brainres.2013.05.011.
  12. Lameu C., Trujillo C.A., Schwindt T.T. et al.Interactions between the NO-citrulline cycle and brain-derived neurotrophic factor in differentiation of neural stem cells. J Biol Chem. 2012; 287(35): 29690-701. doi: 10.1074/jbc.M111.338095.
  13. Glenn J.M., Gray M., Jensen A. et al. Acute citrulline-malate supplementation improves maximal strength and anaerobic power in female, masters athletes tennis players. Eur J Sport Sci. 2016;16(8): 1095-103. doi: 10.1080/17461391.2016.1158321.
  14. Cunniffe B., Papageorgiou M., O'Brien B. et al. Acute citrulline-malate supplementation and high-intensity cycling performance. J Strength Cond Res. 2016; 30(9): 2638-47. doi: 10.1519/JSC.0000000000001338
  15. Дубницкая Э.Б. Стимол при астенических состояниях в специализированной и общемедицинской практике (обзор литературы). Психиатрия и психофармакотерапия. 2010; 4: 12-14. @@Dubnitskaya E.B. Stimol in asthenic conditions in specialized and general medical practice (literature review). Psikhiatriya i psikhofarmakoterapiya = Psychiatry and Psychopharmacotherapy. 2010; 4: 12-14 (In Russ.)
  16. Киселева А.Л. Стимол при астенических состояниях у детей. Практика педиатра. 2012; 4: 63-67. @@Kiseleva A.L. Stimol for asthenic conditions in children. Praktika pediatra = Pediatric Practice. 2012; 4: 63-67 (In Russ.)
  17. Вейн А.М., Окнин В.Ю., Федотова А.В. Применение малата цитруллина (стимола) у лиц с вегетативной дистонией в сочетании с артериальной гипотензией. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999; 1: 30-33. @@Wayne A.M., Oknin V.Yu., Fedotova A.V. The use of citrulline malate (stimol) in patients with vegetative dystonia in combination with arterial hypotension. 1999; 1: 30-33 (In Russ.).
  18. Balderas-Munoz K., Castillo-Martinez L., Orea Tejeda A. et al. Improvement of ventricular function in systolic heart failure patients with oral L-citrulline supplementation. Cardiol J. 2012; 19(6): 612-17. doi: 10.5603/cj.2012.0113.
  19. Иванов Д.Д., Кушниренко С.В. Применение стимола в детской нефрологии: коррекция метаболических нарушений при тубу-лопатиях, хронической почечной недостаточности, гломерулонефрите, пиелонефрите и тубуло интерстициальном нефрите у детей. Современная педиатрия. 2011; 5: 195. @@Ivanov D.D., Kushnirenko S.V. Application of Stimol in pediatric nephrology: metabolic disorders correction at tubulopathy, chronic renal failure, glomerulonephritis, pyelonephritis and tubulointerstitial nephritis in children. Sovremennaya pediatriya = Modern Pediatrics. 2011; 5: 195 (In Russ.)
  20. Громова О.А., Захарова И.Н., Торшин И.Ю. с соавт. О патофизиологической терапии астении у детей препаратами цитруллина малата. Медицинский совет. 2017; 19: 142-48. @@Gromova O.A., Zakharova I.N., Torshin I.Yu. et al. About pathophysiological therapy of asthenia in children by citrulline malate drugs. Meditsinskiy sovet - Medical Council. 2017; 19: 142-48 (In Russ.)].doi: 10.21518/2079-701X-2017-19-142-148.
  21. Cusumano Z.T., Watson M.E. Jr Caparon M.G. Streptococcus pyogenes arginine and citrulline catabolism promotes infection and modulates innate immunity. Infect Immun. 2014; 82(1): 233-42. doi: 10.1128/IAI.00916-13.
  22. Lin I.C., Hsu C.N., Lo M.H. et al. Low urinary citrulline/arginine ratio associated with blood pressure abnormalities and arterial stiff ness in childhood chronic kidney disease. J Am Soc Hypertens. 2016; 10(2): 115-23. doi: 10.1016/j.jash.2015.11.008.
  23. Hafner P., Bonati U., Rubino D. et al. Treatment with L-citrul line and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial. Trials. 2016; 17(1): 389. doi: 10.1186/s13063-016-1503-1.
  24. Giannesini B., Izquierdo M., Le Fur Y. et al. Beneficial effects of citrulline malate on skeletal muscle function in endotoxemic rat. Eur J Pharmacol. 2009; 602(1): 143-47. doi: 10.1016/j.ejphar.2008.11.015.
  25. Giannesini B., Le Fur Y., Cozzone P.J. et al. Citrulline malate supplementation increases muscle efficiency in rat skeletal muscle. Eur J Pharmacol. 2011; 667(1-3): 100-4. doi: 10.1016/j.ejphar.2011.05.068.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies